Finasteride use during pregnancy and early neonatal outcome: a case report
- 228 Downloads
The use of antiandrogen drugs such as finasteride during pregnancy may carry the risk of birth defects, especially hypospadias. We report a 39-year-old woman, with 5 weeks unplanned pregnancy, the patient conceived while receiving daily dose of finasteride 2.5 mg for treatment of alopecia. The patient’s partner was concurrently using finasteride for the same purpose. Ultrasound scans including detailed anatomy were normal throughout pregnancy and the fetal gender was detected to be male. The patient had her delivery at 38+5 weeks’ gestation, by elective cesarean section, a male infant with a weight of 3.58 kg and Apgar score of 9 and 10 at 1 and 5-min, respectively. The infant was healthy with no obvious dysmorphic features. In this case report, maternal use of finasteride in early pregnancy was not associated with external genitalia abnormalities of a male baby. Moreover, maternal exposure to the semen of partner who received finasteride did not adversely affect the short term neonatal outcomes. However, absence of apparent neonatal adverse effects in a single case report does not indicate safety of use. Population-based long term neonatal outcomes are yet to be established.
KeywordsAntiandrogen Congenital abnormalities Fetal toxicity Finasteride Pregnancy Type II 5 α-reductase inhibitor
No funding was received for the current work.
Conflicts of interest
Authors declare no conflict with interest.
- 1.Finasteride. Food and Drug Administration (FDA). Jan 2014. Available at: http://www.fda.gov/. Accessed 6th Dec 2017.
- 9.Ahn KH, Shin J, Hong SC, Han JY, Lee EH, Lee JS, et al. Pregnancy outcomes with paternal exposure to finasteride, a synthetic 5-alpha-reductase inhibitor: a case series. J Clin Toxicol. 2015;5(2):248.Google Scholar
- 10.Overview of off-label use of 5-apha reductase inhibitors in women. Netherland pharmacovigilance center lareb. Apr 2015. Available at: http://www.lareb.nl/?lang=en-GB. Accessed 6th Dec 2017.